APLS Market Cap History
Below is a table of the APLS market cap history going back to 11/9/2017:

Date APLS Market Cap

Also see: APLS Shares Outstanding History
and APLS YTD Return
APLS Historical Market Cap:
+53.11% CAGR
APLS Historical Market Cap: +53.11% CAGR

Mouse over chart for data details
11/9/2017 ...4/29/2022
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications. We show 21 historical shares outstanding datapoints in our APLS shares outstanding history coverage, used to compute APLS market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing APLS market cap history over the course of time is important for investors interested in comparing APLS's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of APLS versus a peer is one thing; comparing APLS market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like APLS can fluctuate over the course of history. With this page we aim to empower investors researching APLS by allowing them to research the APLS market cap history.
Quotes delayed 20 minutes

Email EnvelopeFree APLS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Apellis Pharmaceuticals (APLS) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

APLT Market Cap History
APR Market Cap History
APRE Market Cap History
APRI Market Cap History
APTX Market Cap History
APVO Market Cap History
APYX Market Cap History
AQST Market Cap History
AQXP Market Cap History
ARA Market Cap History
More Healthcare companies »


APLS Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.